GRDXNasdaq

GridAI Technologies Corp.

Healthcare·Oncology·Phase 2·Edinburgh, United Kingdom
OncologyRare DiseaseRespiratoryGastroenterology

GridAI Technologies Corp. (GRDX): 1 pipeline candidate · ~2 mo cash runway. Updated within the last hour.

5.0/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.5

1.8 months

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for GridAI Technologies Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$35.0M

Cash

$386K

Quarterly Burn

$1.8M

Runway

1.8 mo

Revenue

$38K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2026
Today~7 mo out
Catalyst within runway

Pipeline (1 candidate)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

12

Total value held

$732K

HolderSharesValue
renaissance technologies llc183,800$371K
federation des caisses desjardins du quebec47,800$97K
vanguard capital management llc36,586$74K
geode capital management, llc33,270$67K
state street corp23,446$47K
vanguard fiduciary trust co16,345$33K
jane street group, llc12,657$26K
harbour investments, inc.7,994$16K
sbi securities co., ltd.504$1K
citigroup inc1$2

Showing top 10 of 12 institutional holders of GridAI Technologies Corp.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Mr. Jason David Sawyer

Frequently asked questions

How many drug candidates are in GridAI Technologies Corp.'s pipeline?

GridAI Technologies Corp. (GRDX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is GridAI Technologies Corp.'s lead drug candidate?

GridAI Technologies Corp.'s most advanced tracked candidate is adrulipase (Phase 2) for Exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP).

What is GridAI Technologies Corp.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, GridAI Technologies Corp. has approximately 1.8 months of cash runway.

What is GridAI Technologies Corp.'s market capitalization?

GridAI Technologies Corp.'s market capitalization is approximately $35.0M.

Who is the CEO of GridAI Technologies Corp.?

Mr. Jason David Sawyer is the chief executive officer of GridAI Technologies Corp. (GRDX).

Get the full picture on GridAI Technologies Corp.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.